Holding Cancer Hostage: The Revolutionary Science Behind Halda Therapeutics and RIPTACs

This episode tells the extraordinary story of Halda Therapeutics, founded during the 2020 pandemic when renowned Yale professor Craig Crews gathered his team around an outdoor fireplace to brainstorm revolutionary cancer treatments. We explore Crews' journey as a serial biotech entrepreneur and his pioneering RIPTACs (Regulated Induced Proximity TArgeting Chimeras) at Halda -- a groundbreaking "hold and kill" approach that doesn't destroy cancer proteins but holds them hostage instead. The episode covers Halda's dramatic funding journey, their billion-dollar AI partnership with Vantai Therapeutics, and their historic achievement of putting the world's first RIPTAC therapeutic into human clinical trials. 

RIPTACs, Halda Therapeutics, cancer, protein degradation, Craig Crews, drug discovery, pharmaceutical